Background Treatment options for patients with melanoma brain metastasis (MBM) have
changed significantly in the last decade. Few studies have evaluated changes in outcomes …

Patients with melanoma brain metastases (MBM) still have a very poor prognosis. Several
treatment modalities have been investigated in an attempt to improve the management of …

The management of melanoma brain metastases (MBM) includes different therapeutic
modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of …

Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …

Background More than 60% of all stage IV melanoma patients develop brain metastases,
while melanoma brain metastases (MBM) is historically difficult to treat with poor prognosis …

Historically, the prognosis of patients with melanoma brain metastases is poor, with median
overall survival (OS) of 4‐6 months. Little is known of OS in the era of modern systemic …

BACKGROUND: This multicenter study aimed to identify prognostic factors in patients with
brain metastases from malignant melanoma (BM‐MM). METHODS: In a retrospective survey …

Simple Summary Cutaneous melanoma is highly prone to metastasize to the brain, with a
historically poor overall survival of only 4–5 months. Over the past decade, novel drugs such …

Simple Summary Brain metastases are common in melanoma and are often associated with
significant morbidity and mortality. Although many new treatments for melanoma have been …

Importance The treatment of multiple brain metastases (MBM) from melanoma is
controversial and includes surgical resection, stereotactic radiosurgery (SRS), and whole …